array:24 [ "pii" => "S2387020621001108" "issn" => "23870206" "doi" => "10.1016/j.medcle.2020.06.035" "estado" => "S300" "fechaPublicacion" => "2021-04-09" "aid" => "5356" "copyright" => "Elsevier España, S.L.U.. All rights reserved" "copyrightAnyo" => "2020" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Med Clin. 2021;156:360" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0025775320305236" "issn" => "00257753" "doi" => "10.1016/j.medcli.2020.06.041" "estado" => "S300" "fechaPublicacion" => "2021-04-09" "aid" => "5356" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Med Clin. 2021;156:360" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Cartas al Editor</span>" "titulo" => "Indicación de los pulsos de glucocorticoides en pacientes con infección por SARS-CoV-2" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "360" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Indication of glucocorticoid pulses for patients with SARS-CoV-2 infection" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Felipe Blasco Patiño, Ana Elena Guillamón Sánchez" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Felipe" "apellidos" => "Blasco Patiño" ] 1 => array:2 [ "nombre" => "Ana Elena" "apellidos" => "Guillamón Sánchez" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2387020621001108" "doi" => "10.1016/j.medcle.2020.06.035" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020621001108?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775320305236?idApp=UINPBA00004N" "url" => "/00257753/0000015600000007/v1_202103260933/S0025775320305236/v1_202103260933/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S238702062100111X" "issn" => "23870206" "doi" => "10.1016/j.medcle.2020.08.008" "estado" => "S300" "fechaPublicacion" => "2021-04-09" "aid" => "5463" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Med Clin. 2021;156:361" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Reply" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "361" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Respuesta" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Jose Luis Callejas, Norberto Ortego Centeno" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Jose Luis" "apellidos" => "Callejas" ] 1 => array:2 [ "nombre" => "Norberto" "apellidos" => "Ortego Centeno" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0025775320307454" "doi" => "10.1016/j.medcli.2020.08.015" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775320307454?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S238702062100111X?idApp=UINPBA00004N" "url" => "/23870206/0000015600000007/v1_202104020834/S238702062100111X/v1_202104020834/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2387020621000954" "issn" => "23870206" "doi" => "10.1016/j.medcle.2020.02.012" "estado" => "S300" "fechaPublicacion" => "2021-04-09" "aid" => "5171" "copyright" => "Elsevier España, S.L.U." "documento" => "article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Med Clin. 2021;156:359" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Scientific letter</span>" "titulo" => "Acute myocarditis by enzalutamide" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "359" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Miocarditis aguda por enzalutamida" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Virginia Ramos Reyes, Ana Laynez Carnicero, Manuel Morales" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Virginia" "apellidos" => "Ramos Reyes" ] 1 => array:2 [ "nombre" => "Ana" "apellidos" => "Laynez Carnicero" ] 2 => array:2 [ "nombre" => "Manuel" "apellidos" => "Morales" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0025775320302396" "doi" => "10.1016/j.medcli.2020.02.017" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775320302396?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020621000954?idApp=UINPBA00004N" "url" => "/23870206/0000015600000007/v1_202104020834/S2387020621000954/v1_202104020834/en/main.assets" ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Indication of glucocorticoid pulses for patients with SARS-CoV-2 infection" "tieneTextoCompleto" => true "saludo" => "Dear Editor" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "360" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Felipe Blasco Patiño, Ana Elena Guillamón Sánchez" "autores" => array:2 [ 0 => array:4 [ "nombre" => "Felipe" "apellidos" => "Blasco Patiño" "email" => array:1 [ 0 => "hevio@msn.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "Ana Elena" "apellidos" => "Guillamón Sánchez" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Unidad de Diagnóstico Médico y Enfermedades Minoritarias, Servicio de Medicina Interna, Hospital General Universitario de Torrevieja, Torrevieja, Alicante, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Indicación de los pulsos de glucocorticoides en pacientes con infección por SARS-COV-2" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Concerning the article published by Callejas et al.,<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> I would first of all like to thank our colleagues for their efforts in the search for an effective treatment for COVID-19, although on this occasion I have to disagree on the use of glucocorticoid (GC) pulses.</p><p id="par0010" class="elsevierStylePara elsevierViewall">The approach of this article is not new. CGs have been used in other virus-related ARDS, such as SARS, MERS, or influenza A, as already reported in the article by Russell et al.,<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> showing no benefit on mortality at 90 days and evidencing a worse outcome in patients admitted to the ICU. The authors should be aware that these conclusions are in line with the data they provide, the reading of which shows us 83 young patients (median age of 63.9 years) treated with GC pulses, of which, in a follow-up of only 11 days, 12% died or ended up in the ICU and 28% required salvage with tocilizumab; that is, 40% of the treated patients had a poor response. To put this in context, in our series of 96 patients (median age 69.8 years) in a follow-up of 28 days we had a mortality of 14.7% (we included patients in the ICU), 85% were discharged and only 16% of the patients required treatment with tocilizumab or interferon. Obviously, we do not know if both groups are comparable. If we take into account ferritin levels, our patients had a maximum average ferritin concentration of 820 mg/dl, similar to the value described in their study. Without a multivariate analysis that includes variables such as age (the main factor associated with survival), sex, patients who were not treated, or vascular risk factors, it is difficult to establish that GCs increase survival.</p><p id="par0015" class="elsevierStylePara elsevierViewall">Treating this inflammatory response on the assumptions used in autoimmune processes in the case of macrophage activation syndrome with uncontrolled proliferation of T cells is a conceptual error. What happens in coronavirus infection, with significant lymphopenia in the most severe cases, has little to do with this syndrome. The study authors use ferritin and IL-6 levels as parameters to predict cytokine storm, without taking into account that both molecules, and especially IL-6, are high in most viral infections (influenza, hemorrhagic fevers, HIV, HCV, HBV, coronavirus).<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> It has been observed that an increase in the production of IL-6 can be detrimental to the cellular immune response during viral infections, and this is taken advantage of by some viral strains that use the stimulation of IL-6 secretion as an evasion strategy that slows down the humoral response and as a result there is an increase in viral loads.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> The higher the IL-6 level, the higher the viral load. Liu et al.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> found that the viral load is up to 60 times higher in people with a more severe course of COVID-19 infection. The established concept of viral and inflammatory phase is also erroneous, as these patients maintain high viral loads for weeks.</p><p id="par0020" class="elsevierStylePara elsevierViewall">The response to viral infections is a humoral immune response mediated by the activation of T cells. The inflammatory effect of GCs is linked to the inhibition of IL-2, which causes T cell apoptosis. We should not slow down lymphocyte activity in patients with severe lymphopenia.</p><p id="par0025" class="elsevierStylePara elsevierViewall">All of the above would explain why a high percentage of patients treated with GC required tocilizumab. An increase in viral load is to be expected in all of them. It would have been interesting if the authors had reported the viral load and IL-6 levels after the steroid pulses.</p><p id="par0030" class="elsevierStylePara elsevierViewall">In such a short follow-up, it remains to be clarified if any patient has had a recurrence, a reactivation of TB, or how many of these patients had septic shock. Based on the above assumptions, we are against the systematic use (most of them meet the criteria set out by the authors) of GC pulses in patients with COVID-19 pneumonia, as not only do they not show a clear benefit on mortality, but they also entail an increased risk of shock and, contrary to what they state in their article, they lead to a worse outcome and a greater need for tocilizumab.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Blasco Patiño F, Guillamón Sánchez AE. Indicación de los pulsos de glucocorticoides en pacientes con infección por SARS-COV-2. Med Clin (Barc). 2021. <span class="elsevierStyleInterRef" id="intr0005" href="https://doi.org/10.1016/j.medcli.2020.06.041">https://doi.org/10.1016/j.medcli.2020.06.041</span></p>" ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Eficacia de los pulsos de corticoides en pacientes con síndrome de liberaciónde citoquinas inducido por infección por SARS-CoV-2" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J.L. Callejas" 1 => "J.D. Luna" 2 => "J. De la Hera" 3 => "E. Guirao" 4 => "M. Colmenero" 5 => "N. Ortego" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.medcli.2020.04.018.2" "Revista" => array:3 [ "tituloSerie" => "Med Clin (Barc)." "fecha" => "2020" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7603093" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "C.D. Russell" 1 => "J.E. Millar" 2 => "J.K. Baillie" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(20)30317-2" "Revista" => array:6 [ "tituloSerie" => "Lancet." "fecha" => "2020" "volumen" => "395" "paginaInicial" => "473" "paginaFinal" => "475" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32043983" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Velazquez-Salinas L., Verdugo-Rodriguez A., Rodriguez L., Boca M.V. The role ofinterleukin 6 during viral infection [accessed 26 Jun 2020]. Available at: <a target="_blank" href="https://www.frontiersin.org/articles/10.3389/fmicb.2019.01057/full">https://www.frontiersin.org/articles/10.3389/fmicb.2019.01057/full</a>." ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Innate immune evasion strategies of DNA and RNA viruses" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "D.C. Beachboard" 1 => "S.M. Horner" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.mib.2016.05.015" "Revista" => array:6 [ "tituloSerie" => "Curr Opin Microbiol." "fecha" => "2016" "volumen" => "32" "paginaInicial" => "113" "paginaFinal" => "119" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27288760" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Viral dynamics in mild and severe cases of COVID-19" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Y. Liu" 1 => "L.-M. Yan" 2 => "L. Wan" 3 => "T.-X. Xiang" 4 => "A. Le" 5 => "J.-M. Liu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S1473-3099(20)30232-2" "Revista" => array:6 [ "tituloSerie" => "Lancet Infect Dis." "fecha" => "2020" "volumen" => "20" "paginaInicial" => "656" "paginaFinal" => "657" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32199493" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/23870206/0000015600000007/v1_202104020834/S2387020621001108/v1_202104020834/en/main.assets" "Apartado" => array:4 [ "identificador" => "43309" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Letters to the Editor" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/23870206/0000015600000007/v1_202104020834/S2387020621001108/v1_202104020834/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020621001108?idApp=UINPBA00004N" ]
Journal Information
Vol. 156. Issue 7.
Pages 360 (April 2021)
Share
Download PDF
More article options
Vol. 156. Issue 7.
Pages 360 (April 2021)
Letter to the Editor
Indication of glucocorticoid pulses for patients with SARS-CoV-2 infection
Indicación de los pulsos de glucocorticoides en pacientes con infección por SARS-COV-2
Visits
261
Felipe Blasco Patiño
, Ana Elena Guillamón Sánchez
Corresponding author
Unidad de Diagnóstico Médico y Enfermedades Minoritarias, Servicio de Medicina Interna, Hospital General Universitario de Torrevieja, Torrevieja, Alicante, Spain
This item has received
Article information
These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscribe
Purchase
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail